Shaanxi Panlong Pharmaceutical (SZ:002864) Xin Lang Cai Jing·2025-09-26 08:28Core Viewpoint - The company, Panlong Pharmaceutical, has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of the generic drug, Loxoprofen Sodium Gel Patch, which is intended for treating osteoarthritis, muscle pain, and swelling or pain after injuries [1] Group 1 - The product is a gel patch with significant anti-inflammatory and analgesic effects [1] - The acceptance number for the application is CYHS2503515, and it is classified as a Class 4 chemical drug [1] - The company will fulfill its information disclosure obligations in accordance with relevant regulations regarding subsequent developments [1] Group 2 - This matter is not expected to have a significant impact on the company's business operations in the short term [1]